Iron-regulated Protein Vaccine Technology

It makes good scientific sense to make a vaccine against [bacterial] proteins that bond with iron.
Dr. Gregory Poland, M.D., Director of Mayo Clinical Vaccine Research Group



Syntiron develops innovative microbial vaccines to help people live healthier, more productive lives. Our antigen discovery and purification technology targets proteins that acquire iron, a nutrient required for bacterial survival. Nearly all species of bacteria require iron for survival. Under iron-limiting conditions, many species of bacteria secrete small iron-chelating molecules termed ‘siderophores’ that bind iron with an extremely high affinity, essentially stealing iron from host proteins. Siderophore receptor proteins embedded in the membrane of the bacteria then bind the iron-bound siderophores and interact with other membrane-associated proteins to internalize iron. Additional transport proteins involved with the import of small molecules are also expressed under iron-limiting conditions. These surface-expressed proteins are not subject to the variability associated with antimicrobial resistance mechanisms and surface carbohydrates, making them ideal vaccine antigens. Our proprietary platform enables rapid identification and purification of the iron-regulated proteins directly from the host cell or as recombinants for use in vaccine development.

The approach was validated by our affiliate Epitopix in clinical and commercial veterinary trials in hundreds of millions of animals, which demonstrated the safety, efficacy, and cost-efficiency of the platform. Epitōpix currently manufactures two USDA-approved cattle vaccines for Salmonella Newport and E. coli O157:H7 that are licensed and marketed by Zoetis (formerly Pfizer Animal Health). With the exclusive license for human applications, Syntiron specializes in preclinical development and seeks partnerships to advance the technology toward commercialization.